Skip to Main Content

Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs that target bone marrow diseases to its research pipeline.

The all-cash deal values Imago at $36 per share, or a 107% premium from its closing price on Friday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment